Maze Therapeutics, Inc.
MAZE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001842295
In the last 90 days, Maze Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 161 institutions reported holding it in 13F filings for Q2 2026, worth $1.75B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Superinvestors holding MAZE, Q2 2026
1 superinvestor reports holding Maze Therapeutics, Inc. on Form 13F, worth $10.9M in total. Weight is Maze Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| HHLR Advisors (Hillhouse)Zhang Lei | 1.3% | 366,028 | $10.9M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of MAZE each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−20.0%)
Q1 2025
1 superinvestor holding at quarter end